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Abstract
Objective:  To  evaluate  the  outcome  of  children  with  severe  acquired  aplastic  anemia  treated
with rabbit  antithymocyte  globulin  and  cyclosporine  as  ﬁrst-line  treatment  at  this  institution.
Methods:  Retrospective  analysis  of  26  pediatric  patients  with  aplastic  anemia,  treated  between
1996  and  2011  with  rabbit  antithymocyte  globulin  plus  cyclosporine.
Results:  The  overall  response  rate  at  six  months  was  34.6%  (9/26),  and  the  cumulative  incidence
of relapse  was  26.5%  (95%  conﬁdence  interval  [CI]:  1.4%-66%)  at  5  years.  The  cumulative  inci-
dence  of  clonal  evolution  after  immunosuppressive  therapy  was  8.3%  (95%  CI:  0.001%-53.7%)  at
ﬁve  years  with  both  clonal  evolutions  in  non  -responders  who  acquired  monosomy  7  karyotype.
The  overall  survival  at  ﬁve  years  was  73.6%  (95%  CI:  49.2%-87.5%).
Conclusions:  The  present  results  conﬁrm  the  poor  response  rate  with  rabbit  antithymocyte
globulin as  ﬁrst  therapy  in  pediatrics  patients,  similar  to  what  has  been  reported  for  patients
of  all  ages.  This  conﬁrmation  is  problematic  in  Brazil,  given  the  lack  of  horse  antithymocyte
globulin in  many  markets  outside  the  United  States.
©  2014  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  
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Resultado  de  crianc¸as  com  anemia  aplástica  grave  adquirida  tratadas  com  globulina
antitimocítica  de  coelho  e  ciclosporina  A
Resumo
Objetivo:  Avaliar  o  resultado  de  crianc¸as  com  anemia  aplástica  grave  adquirida  tratadas  com
globulina antitimocítica  de  coelho  e  ciclosporina  como  tratamento  inicial  em  nosso  instituto.
Métodos:  Análise  retrospectiva  de  26  pacientes  pediátricos  com  anemia  aplástica  tratados  entre
1996  e  2011  com  globulina  antitimocítica  de  coelho  e  ciclosporina.
Resultados:  A  taxa  de  resposta  geral  em  seis  meses  foi  de  34,6%  (9/26),  e  a  incidência  acumu-
lada de  recorrência  foi  de  26,5%  (intervalo  de  conﬁanc¸a [IC]  de  95%,1,4%-66%)  em  cinco  anos.  A
incidência  acumulada  de  evoluc¸ão  clonal  após  a  terapia  imunossupressora  foi  de  8,3%  (IC  95%,
0,001%-53,7%)  em  cinco  anos,  com  ambas  as  evoluc¸ões  clonais  em  pacientes  sem  resposta  que
adquiriram  o  cariótipo  com  monossomia  7.  A  sobrevida  geral  em  cinco  anos  foi  de  73,6%  (IC
95%,  49,2%-87,5%).
Conclusões:  Nossos  resultados  conﬁrmam  a  baixa  taxa  de  resposta  com  globulina  antitimocítica
de coelho  como  terapia  inicial  em  pacientes  pediátricos,  da  mesma  forma  como  relatado  para
pacientes  de  todas  as  idades.  Essa  conﬁrmac¸ão  é  problemática  em  nosso  país  devido  à  falta
de  globulina  antitimocítica  de  cavalo  em  muitos  mercados  fora  dos  Estados  Unidos,  incluindo  o
Brasil.
©  2014  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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sis of  Fanconi  anemia.  Bone  marrow  biopsy  and  aspirate,
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evere  aplastic  anemia  (SAA)  is  a  rare  hematological  dis-
ase characterized  by  pancytopenia  and  a  hypocellular  bone
arrow.  In  SAA,  cellular  marrow  elements  are  replaced
y fat  as  a  result  of  an  immune-mediated  destruction  of
tem and  progenitor  cells.1 Until  recently,  it  was  believed
hat fat  replacement  was  a  benign  process;  however,
ecent data  suggest  that  it  might  be  a  negative  regu-
ator of  hematopoiesis,  contributing  to  marrow  failure.2
ematopoiesis  can  be  restored  in  SAA  following  hematopoi-
tic stem  cell  transplantation  (HSCT)  or  immunosuppressive
herapy (IST).  In  children  and  young  adults,  HSCT  is  pre-
erred when  a  histocompatible  sibling  donor  is  available;  for
ll other  patients,  IST  is  often  employed  as  ﬁrst  therapy.3--5
he  standard  IST  is  with  a  combination  of  horse  antithy-
ocyte globulin  (ATG)  and  cyclosporine  (CsA).6 More  potent
ymphocytotoxic agents,  such  as  rabbit  ATG,  alemtuzumab,
nd cyclophosphamide,  have  yielded  disappointing  results
n treatment-naïve  SAA  due  to  lack  of  efﬁcacy  and/or
ncreased toxicity.7--10 Response  rates  to  horse  ATG/CsA  have
een consistent  across  studies  in  the  US,  Europe,  and  Japan,
nd have  varied  between  60%  and  75%.1,4,11--13 In  general,
hildren have  a  higher  hematologic  response  rate  in  the  70%
o 80%  range,  while  older  adults  (>  40-50  years  of  age)  have
eported response  rates  in  the  50%  to  60%  range.14--17
Rabbit  ATG  is  manufactured  similarly  to  horse  ATG,
ut has  greater  lymphocytotoxic  properties  on  a  weight
asis.18,19 Human  T-cells  derived  from  a  thymus  or  T-cell
ine is  used  to  sensitize  an  animal,  whether  horse  or  rabbit,
hich will  produce  polyclonal  antibodies  with  a  multitude  of
peciﬁcities to  molecules  expressed  in  human  T  cells.  This
olyclonal sera  is  then  puriﬁed  for  administration  in  humans.
abbit ATG  has  been  successful  in  salvaging  SAA  patients
fter initial  horse  ATG  failure  and  in  kidney  allograft,  and
i
t
cas  shown  to  be  superior  to  horse  ATG  in  head-to-head
omparison.20--22 However,  when  given  as  ﬁrst  therapy,  out-
omes with  rabbit  ATG  were  inferior  to  horse  ATG  in  a
andomized study.8 Follow-up  retrospective  reports  have
onﬁrmed a  lower  response  rate  in  patients  treated  with  rab-
it ATG  as  ﬁrst  therapy  when  compared  to  horse  ATG.23--26
owever,  the  majority  of  the  reports  have  not  focused  on
hildren. This  article  aimed  to  report  the  results  in  pedi-
tric patients  who  received  rabbit  ATG  as  ﬁrst  therapy  for
AA treated  at  the  Instituto  da  Crianc¸a of  the  Universidade
e São  Paulo,  São  Paulo,  Brazil.
atients and Methods
atients
his  study  included  consecutive  patients  with  SAA  who
eceived rabbit  ATG/CsA  between  August  of  1996  and  of
une 2011  at  the  Instituto  da  Crianc¸a of  the  Universidade
e São  Paulo.  Due  to  the  unavailability  of  the  horse  ATG
n this  service  and  in  Brazil  since  2007,  rabbit  ATG  became
he standard  immunosuppressor  in  SAA  patients  without  an
LA-identical sibling  donor.  All  patients  met  the  criteria  for
AA, deﬁned  as  a  bone  marrow  cellularity  of  less  than  30%
nd severe  pancytopenia  with  at  least  two  of  the  follow-
ng peripheral  blood  count  criteria:  (1)  absolute  neutrophil
ount (ANC)  <  0,5  x  109/lL  (2)  absolute  reticulocyte  count
ARC) <  60x109/L;  platelet  count  <  20x109/L.27 Exclusion
riteria were:  (1)  abnormal  cytogenetics,  (2)  bone  marrow
orphology consistent  with  myelodysplasia,  and  (3)  diagno-ncluding cytogenetics,  were  performed  before  initiating
herapy. Fanconi  anemia  was  excluded  by  the  absence  of
hromosomal changes  after  exposure  in  vitro  of  lymphocytes
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CI: 16%-53%).  Three  patients  responded  between  six  and
12 months  resulting  in  a  response  rate  of  46.2%  (95%  CI:
27%-65%) at  this  time  period.  The  cumulative  incidence  of
relapse was  26.5%  (95%  CI:  1.4%-66%)  at  ﬁve  years  (Fig.  1,
Table  1  Demographic  and  hematological  characteristics.
Patient  characteristics  Number  of  patients
(n =  26)
Male/  female  14/12  (53.8%  /  46.2%)
Median  age  at  diagnosis,  years  8.1  (1.6-15)
Cause  of  aplastic  anemia
Idiopatic 24  (92.3%)
Associated hepatitis  2  (7.7%)
Severity of  disease  at  diagnosis
Very severe  (neutrophil
count <  0.2  x  109/L)
14 (53.8%)
Severe (neutrophil  count  <
0.5  x  109/L)
12 (46.2%)
Median time  between
diagnosis and  treatment
initiation, days
75.7  (7-300)
Response  to  treatment  at  six  months
Complete  response  3  (11.6%)
Partial response  6  (23.0%)
No response  17  (65.4%)
Relapse 4  (15.0%)
Clonal evolution  (monosomy  7)  2  (7.6%)
Outcome
Alive with  transfusion
independency
16  (61.6%)
Alive with  transfusion
dependency
4  (15.4%)Outcome  of  children  with  severe  acquired  aplastic  anemia  
to  diepoxibutane  (Deb-test).  Patients  were  hospitalized  for
the administration  of  rabbit  ATG  and  discharged  when  clin-
ically stable,  usually  after  approximately  three  weeks.  The
local medical  ethics  committee  approved  this  study,  and
data were  obtained  from  written  and  computerized  material
records.
Treatment  regimen
An  initial  intravenous  test  dose  was  performed  on  all
patients to  assess  for  allergic  hypersensitivity.  Rabbit
ATG (Timoglobulina®,  Genzyme,  Cambridge,  MA,  USA)  was
administered at  a  dose  of  5  mg/kg/d  i.v  for  ﬁve  consecutive
days. Serum  sickness  prophylaxis  was  with  methylpred-
nisolone at  2  mg/kg/d  was  given  prior  to  the  ﬁrst  dose  of
ATG, and  was  continued  for  ten  days  and  then  tapered  over
the subsequent  seven  days.  Cyclosporine  was  initiated  on
day 6 at  10  mg/kg/d  p.o  in  divided  doses  q12  h.  CsA  was
administered for  at  least  six  months,  adjusted  to  blood  lev-
els (therapeutic  range  between  150  and  250  ng/mL).
Supportive  care
Granulocyte  colony  stimulating  factor  (G-CSF)  was  adminis-
tered at  a  dose  of  5  g/kg  subcutaneously  from  day  +1  to  day
+30 to  maintain  neutrophils  >0.5  x  109/Lto  avoid  infections.
Itraconazole was  used  as  prophylaxis  for  fungal  infection
at a  dose  of  100  mg/d  for  at  least  one  month  after  rab-
bit ATG.  Other  prophylactic  antibiotics  were  not  routinely
administered.
Red blood  cells  were  transfused  in  patients  with  symp-
tomatic anemia  or  to  maintain  a  hemoglobin  level  higher
than 9  g/dL.  Platelets  were  transfused  prophylactically  in
all patients  with  a  platelet  count  lower  than  10  x  109/L.
Platelets were  transfused  at  a  higher  threshold  (20  x  109/L)
in the  presence  of  fever  and/or  clinical  bleeding.
Deﬁnitions
Compete  response  (CR)  was  deﬁned  as  transfusion  indepen-
dence associated  with  hemoglobin  (Hb)  >  110  g/L,  neutrophil
count >  1.5  x  109/L,  and  platelet  count  >  100  x  109/L.  Partial
response (PR)  was  deﬁned  as  transfusion  independence,  but
not  meeting  the  blood  count  criteria  for  CR.  All  remissions
had to  be  conﬁrmed  by  two  blood  counts  at  least  four  weeks
apart. Response  was  evaluated  at  180  days  from  treatment.
Relapse was  indicated  by  the  requirement  of  red  blood  cell
and/or platelet  transfusion  after  transfusion  independence
lasting three  or  more  months.
Clonal  evolution  was  deﬁned  as  the  appearance  of  a  new
clonal disorder  on  cytogenetics  or  characteristic  morpho-
logic changes  on  bone  marrow  examination.
Statistical  analysis
Summary  statistics,  including  means,  proportions,  and  their
corresponding standard  deviations  were  used  to  describe
patients’ age,  gender,  and  other  baseline  characteristics.
Sample proportions  and  their  95%  conﬁdence  intervals  (CIs)
were used  to  describe  the  six-month  response  rates  for
patients categorized  by  discrete  risk  factors.  Long-term525
urvival  probabilities  for  patients  with  discrete  and  con-
inuous baseline  risks  were  evaluated  using  Kaplan-Meier
stimates; patients  who  were  lost  to  follow-up  were  counted
s censored.  Median  follow-up  was  determined  by  the
everse censoring  method.  The  numerical  results  were  com-
uted  using  GraphPad  Prism  (GraphPad,  CA,  USA).
esults
 total  of  26  patients  with  SAA  were  treated  with  rabbit
TG/CsA. The  median  follow-up  for  the  cohort  was  4.3  years
interval: 0.02-12.2).  The  median  age  was  8.1  years  (range:
.6-15). The  absolute  neutrophil  count  was  less  than  0.2
 109/L  at  presentation  in  14  (53.8%)  and  less  than  0.5  x
09/L  in  12  (46.2%)  patients.  In  92.3%  of  cases,  there  was
o apparent  precipitating  event  (idiopathic  SAA),  and  two
atients (7.7%)  had  SAA  following  seronegative  hepatitis.
he interval  between  diagnosis  and  start  of  treatment  was  a
edian of  75.7  days  (range:  7-300  days).  Additional  patient
haracteristics are  shown  in  Table  1.
The  overall  response  rate  at  six  months  was  34.6%  (95%Dead 6  (23.0%)
Median time  of  follow-up,
years
4.3  (0.02--12.2)
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Figure  1  Long  term  outcomes  following  initial  therapy  with
rabbit ATG.  (Top)  The  cumulative  incidence  of  relapse  was  26.5%
(95% CI:  0.1%-68%)  at  ﬁve  years  among  responders  to  rabbit  ATG;
(Middle) The  cumulative  incidence  of  clonal  evolution  was  8.3%
(95% CI:  0.001%-53.7%)  among  all  patients;  (Bottom)  The  overall
survival at  ﬁve  years  was  73.6%  (95%  CI:  49.2%-87.5%)  among  all
patients. Patients  were  censored  at  the  time  of  death  or  last
follow-up. Median  follow-up  for  all  patients  was  4.3  years.  The
graph was  truncated  at  six  years.  Dotted  lines,  bottom  panel
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Represents 95%  CI.  Number  at  risk  is  depicted  for  the  Kaplan-
eier survival  curve  only.
op  panel).  The  cumulative  incidence  of  clonal  evolution
as 8.3%  (95%  CI:  0.001-53.7%;  Fig.  1,  middle  panel).  The
wo clonal  evolutions  were  in  non-responders  who  acquired
 monosomy  7  karyotype,  and  both  died  due  to  infectious
omplications. The  overall  survival  at  ﬁve  years  was  73.6%
95% CI:  49.2%-87.5%;  Fig.  1,  bottom  panel).  There  were
our deaths  from  complications  of  SAA  (septicemia)  and  two
eaths secondary  to  clonal  evolution.iscussion
n  general,  children  have  a  more  favorable  outcome  com-
ared to  older  patients  with  aplastic  anemia  who  are  treatedGaranito  MP  et  al.
ith  IST.  The  response  rates  are  higher  in  children  and  over-
ll survival  among  responders  is  excellent.17 Although  there
asn’t been  a randomized  study  comparing  IST  to  HSCT  in
ediatric patients,  most  patients  in  this  age  group  undergo
 matched  related  HSCT  if  a  histocompatible  sibling  is  avail-
ble. However,  IST  in  this  age  group  also  produces  excellent
esults as  reported  by  the  European  Group  for  Blood  and
arrow Transplantation  (EBMT),  where  survival  outcomes
or IST  and  HSCT  as  ﬁrst  therapy  were  >  90%.28 Most  of
he IST  experience  in  SAA  is  with  horse  ATG;  however,  since
007, this  formulation  is  no  longer  available  in  many  parts
f the  world  including  Brazil.  Thus,  rabbit  ATG  became  the
nly formulation  available  outside  the  United  States,  and
t is  used  interchangeable  with  horse  ATG  by  hematologists
orldwide. However,  outcomes  from  a  large  prospective  and
everal other  retrospective  analysis  have  demonstrated  that
abbit ATG  was  less  efﬁcacious  than  horse  ATG  as  ﬁrst  ther-
py in  SAA.  At  this  center,  rabbit  ATG  is  still  used,  and  a
igh dose  of  ATG  was  adopted  as  initial  therapy  in  children
ho were  not  transplant  candidates  to  verify  whether  the
esponse would  be  better  when  compared  with  the  usual
oses.
The authors’  experience  with  rabbit  ATG  as  ﬁrst  line  ther-
py in  a  small  pediatric  cohort  was  disappointing.  Although
here was  no  historical  control,  the  results  were  far  infe-
ior to  the  70%  80%  response  rate  reported  in  the  literature
ith horse  ATG  in  children  under  the  age  of  18.  The  present
elative sample  size  (with  wide  conﬁdence  intervals)  is  a
imitation to  our  analysis;  notwithstanding,  the  observed
esponse rate  in  this  pediatric  cohort  was  lower  than  what
s observed  in  this  patient  population  following  horse  ATG
herapy. The  experience  of  only  a  34.6%  response  rate
t six  months  is  very  similar  to  the  large  NIH  random-
zed trial,  and  is  in  accordance  with  other  retrospective
esults.8,24,26 A  small  retrospective  study  showed  a  similarly
ow response  rate  in  children,  where  only  13,3%  of  patients
2/15) responded  to  rabbit  ATG.29 Some  reports  suggest  that
he response  to  rabbit  ATG  as  ﬁrst  therapy  is  not  too  dis-
imilar from  what  observed  with  horse  ATG;  however,  the
esponse rate  to  rabbit  ATG  in  these  retrospective  analysis
end to  be  lower  than  what  has  been  reported  in  other  large
tudies with  this  agent.30,31
The  present  results  suggest  that  the  response  rate  of
abbit ATG  as  ﬁrst  therapy  is  poor  in  pediatrics  patients,  sim-
larly to  what  has  been  reported  for  patients  of  all  ages.  The
onﬁrmation of  this  hypothesis  in  this  patient  population  is
ogistically complex,  given  the  lack  of  horse  ATG  outside  the
nited States  market.
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